BioCentury | Apr 17, 2019
Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...
BioCentury | Mar 31, 2016
Translation in Brief

Slow and steady

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bind Therapeutics Inc. (NASDAQ:BIND) have joined forces to stretch the therapeutic index of a kinase inhibitor that had stumbled in the clinic. The partners developed a nanoparticle formulation that slowed...
BioCentury | Dec 3, 2015
Product R&D

Eyeing fewer needles

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised...
BioCentury | May 7, 2015
Translation in Brief

Less is more

A single copy deletion of RNA polymerase II in colorectal cancer makes the tumors 10 times more sensitive to Heidelberg Pharma's ADCs Heidelberg Pharma's collaborators at the University of Texas MD Anderson Cancer Center have...
BioCentury | Oct 6, 2014
Finance

Atlas' next chapter

...Pharmaceuticals Inc. , which raised $30 million in a 2004 IPO; and then-preclinical cancer play Adnexus Therapeutics Inc....
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...
BioCentury | Mar 1, 2012
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens RNA sequencing of multiple drug-resistant cells to identify therapeutic targets and mechanisms of action In vitro studies suggest RNA sequencing of drug-resistant cells could...
BioCentury | Sep 22, 2011
Cover Story

Finding the repurpose

A Stanford University team has used a computational approach to analyze publicly available gene expression profiles and identified two drug repurposing opportunities. 1,2 The researchers found that the anticonvulsant topiramate could have use in inflammatory...
BioCentury | Sep 19, 2011
Clinical News

Ceplene histamine dihydrochloride: FDA action

According to EpiCept, FDA indicated the biotech should compare Ceplene plus IL-2 vs. IL-2 monotherapy using OS as the primary endpoint as part of a registration trial in order to isolate the effect of Ceplene...
BioCentury | Aug 22, 2011
Company News

BAC B.V., Bristol-Myers deal

...protein in human serum. Bristol-Myers gained rights to the compounds through its 2007 acquisition of Adnexus Therapeutics Inc....
Items per page:
1 - 10 of 77
BioCentury | Apr 17, 2019
Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...
BioCentury | Mar 31, 2016
Translation in Brief

Slow and steady

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bind Therapeutics Inc. (NASDAQ:BIND) have joined forces to stretch the therapeutic index of a kinase inhibitor that had stumbled in the clinic. The partners developed a nanoparticle formulation that slowed...
BioCentury | Dec 3, 2015
Product R&D

Eyeing fewer needles

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised...
BioCentury | May 7, 2015
Translation in Brief

Less is more

A single copy deletion of RNA polymerase II in colorectal cancer makes the tumors 10 times more sensitive to Heidelberg Pharma's ADCs Heidelberg Pharma's collaborators at the University of Texas MD Anderson Cancer Center have...
BioCentury | Oct 6, 2014
Finance

Atlas' next chapter

...Pharmaceuticals Inc. , which raised $30 million in a 2004 IPO; and then-preclinical cancer play Adnexus Therapeutics Inc....
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...
BioCentury | Mar 1, 2012
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens RNA sequencing of multiple drug-resistant cells to identify therapeutic targets and mechanisms of action In vitro studies suggest RNA sequencing of drug-resistant cells could...
BioCentury | Sep 22, 2011
Cover Story

Finding the repurpose

A Stanford University team has used a computational approach to analyze publicly available gene expression profiles and identified two drug repurposing opportunities. 1,2 The researchers found that the anticonvulsant topiramate could have use in inflammatory...
BioCentury | Sep 19, 2011
Clinical News

Ceplene histamine dihydrochloride: FDA action

According to EpiCept, FDA indicated the biotech should compare Ceplene plus IL-2 vs. IL-2 monotherapy using OS as the primary endpoint as part of a registration trial in order to isolate the effect of Ceplene...
BioCentury | Aug 22, 2011
Company News

BAC B.V., Bristol-Myers deal

...protein in human serum. Bristol-Myers gained rights to the compounds through its 2007 acquisition of Adnexus Therapeutics Inc....
Items per page:
1 - 10 of 77